NCT00540670View on ClinicalTrials.gov

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Conditions
Coronary Artery Disease
Interventions
DRUG

E5555 50 mg

E5555 50 mg (tablet) taken orally, once a day.

DRUG

E5555 100 mg

E5555 100 mg (tablet) taken orally, once a day.

DRUG

E5555 200 mg

E5555 200 mg (tablet) taken orally, once a day.

DRUG

Placebo

Placebo (tablet) taken orally, once a day.

Trial Locations (25)

Unknown

Ichinomiya

Gifu

Ōgaki

Asahikawa

Chitose

Sapporo

Tomakomai

Himeji

Nishinomiya

Tsuchiura

Kanazawa

Yokohama

Kumamoto

Matsusaka

Tsu

Osaka

Sayama

Kitamoto

Saitama

Shizuoka

Bunkyo-ku

Musashino

Ōta-ku

Shinjuku-ku

Tachikawa

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT00540670 - A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease | Biotech Hunter | Biotech Hunter